Filter the latest scan's published facts — sector, size, yield, valuation — or rank them with a preset: cheapest, fastest growing, most profitable. Every view shows what is in the filings and prices; none ranks opportunity. The model behind the statuses showed no predictive power, and nothing here is a recommendation.
Scan of 2026-08-31 · 2,409 names scored · prices as of that date
Lowest valid-in-sector trailing valuation multiples today, latest scan: each name's sector percentiles on earnings yield, FCF yield, P/S, P/B, P/TBV and P/CFO, averaged (only the metrics valid in its sector — a REIT is never ranked by GAAP P/E here). “Cheapest” is a fact about trailing multiples versus sector peers, not a forecast that they re-rate.
Tested the unforgiving way: a composite ranking built from these same point-in-time filings (2017-01-31 to 2026-05-29) showed no measurable predictive power (mean IC 0.0168, t = 1.21), and its top quintile did not beat holding everything even before costs. Ranks like these describe today's record; they do not predict tomorrow's return.
284 names — page 2 of 6 · sector: Pharma & chemicals · Export CSV
| # | Ticker | Company | Sector | Cheap composite | P/E (trailing) | P/S (trailing) | FCF yield | Own 5y |
|---|---|---|---|---|---|---|---|---|
| 51 | ORMP | Oramed Pharmaceuticals Inc. | Pharma & chemicals | 67.5 | 1.9× | 103×FY |
Never the absolute multiple alone. A P/E of 9 is a fact; whether it is low depends on what you hold it against.
The five-year window is the empirically privileged one. Cheap against its sector and cheap against its own history are different claims, and a stock can be one without being the other — which is the whole reason both columns are shown rather than blended into a single score.
| -4.2% |
| +0.9σ |
| 52 | ZTS | ZOETIS INC. | Pharma & chemicals | 67.1 | 12.1× | 3.4× | 6.9% | +3.0σ |
| 53 | KRO | Kronos Worldwide, Inc. | Pharma & chemicals | 66.4 | — | 0.5× | 1.1% | +0.1σ |
| 54 | UTHR | United Therapeutics Corp | Pharma & chemicals | 65.8 | 16.7× | 6.8× | 4.7% | −1.2σ |
| 55 | ESI | Element Solutions Inc. | Pharma & chemicals | 65.6 | 64.6× | 3.4× | — | +1.3σ |
| 56 | NEU | NewMarket Corporation | Pharma & chemicals | 65.3 | 20.1× | 3.1× | 5.9% | +0.1σ |
| 57 | BIIB | Biogen Inc. Common Stock | Pharma & chemicals | 65.1 | 27.1× | 3.7× | 6.5% | −0.0σ |
| 58 | ELAN | Elanco Animal Health Incorporated Common Stock | Pharma & chemicals | 64.5 | — | 2.4× | 2.6% | −0.4σ |
| 59 | CF | CF Industries Holding, Inc. | Pharma & chemicals | 64.5 | — | 2.8× | 7.7% | −1.4σ |
| 60 | IFF | International Flavors & Fragrances Inc. | Pharma & chemicals | 64.1 | — | 2.0× | 1.8% | −0.3σ |
| 61 | LTBR | Lightbridge Corp. | Pharma & chemicals | 64.1 | — | — | -6.0% | +0.7σ |
| 62 | ROG | Rogers Corporation | Pharma & chemicals | 63.9 | — | 2.7× | 3.1% | +0.2σ |
| 63 | INCY | Incyte Genomics Inc | Pharma & chemicals | 63.6 | 17.2× | 4.6× | 6.2% | +1.2σ |
| 64 | PAHC | Phibro Animal Health Corporation Class A | Pharma & chemicals | 63.5 | 16.1× | 1.0× | 2.2% | +0.4σ |
| 65 | IQV | IQVIA Holdings Inc. | Pharma & chemicals | 63.2 | 31.5× | 2.6× | 4.9% | −0.1σ |
| 66 | IPAR | Interparfums, Inc. Common Stock | Pharma & chemicals | 63.0 | 22.2× | 2.5× | 5.3% | +0.9σ |
| 67 | ABUS | Arbutus Biopharma Corporation Common Stock | Pharma & chemicals | 61.9 | 6.2× | 5.2× | -3.4% | +1.4σ |
| 68 | NEOG | Neogen Corp | Pharma & chemicals | 61.7 | — | 2.9× | -0.1% | +0.3σ |
| 69 | RPRX | Royalty Pharma plc Class A Ordinary Shares | Pharma & chemicals | 61.6 | 42.8× | 14.5× | 7.4% | −1.3σ |
| 70 | WLK | Westlake Corporation | Pharma & chemicals | 61.2 | — | 0.9× | -5.3% | −1.9σ |
| 71 | PG | Procter & Gamble Company | Pharma & chemicals | 60.8 | 20.3× | 3.9× | 4.4% | +1.3σ |
| 72 | NBIX | Neurocrine Biosciences Inc | Pharma & chemicals | 60.3 | 23.2× | 5.0× | 5.4% | +1.5σ |
| 73 | ADMA | ADMA Biologics, Inc. | Pharma & chemicals | 59.6 | 13.2× | 4.3× | 4.9% | +0.8σ |
| 74 | RPM | RPM International, Inc. | Pharma & chemicals | 59.0 | 20.0× | 1.7× | 3.9% | +0.3σ |
| 75 | GILD | Gilead Sciences Inc | Pharma & chemicals | 59.0 | 19.7× | 6.1× | 5.6% | −1.3σ |
| 76 | CHD | Church & Dwight Co., Inc. | Pharma & chemicals | 58.7 | 33.0× | 3.9× | 4.4% | +0.8σ |
| 77 | ABT | Abbott Laboratories | Pharma & chemicals | 58.3 | 35.1× | 4.9× | 3.3% | +0.4σ |
| 78 | ZVRA | Zevra Therapeutics, Inc. Common Stock | Pharma & chemicals | 57.4 | 5.6× | 5.7× | 1.7% | +1.0σ |
| 79 | ACAD | Acadia Pharmaceuticals Inc. | Pharma & chemicals | 57.2 | 13.2× | 4.5× | 2.3% | +0.7σ |
| 80 | EXEL | Exelixis Inc | Pharma & chemicals | 57.0 | 16.6× | 5.8× | 6.6% | +0.6σ |
| 81 | APD | Air Products & Chemicals, Inc. | Pharma & chemicals | 56.9 | 32.7× | 5.5× | — | +0.8σ |
| 82 | XERS | Xeris Biopharma Holdings, Inc. Common Stock | Pharma & chemicals | 56.9 | 121× | 4.6× | 3.3% | +0.9σ |
| 83 | SUPN | Supernus Pharmaceuticals, Inc. | Pharma & chemicals | 56.3 | — | 3.3× | 3.2% | −1.4σ |
| 84 | BNTC | Benitec Biopharma Inc. Common Stock | Pharma & chemicals | 55.6 | — | — | -5.4% | +0.9σ |
| 85 | CRL | Charles River Laboratories International, Inc. | Pharma & chemicals | 55.5 | — | 3.4× | 2.8% | −0.9σ |
| 86 | ASMB | Assembly Biosciences, Inc | Pharma & chemicals | 55.2 | — | 7.4×FY | -7.5% | +0.8σ |
| 87 | LNTH | Lantheus Holdings, Inc | Pharma & chemicals | 54.6 | 23.5× | 4.2× | 6.2% | +0.6σ |
| 88 | VNDA | Vanda Pharmaceuticals Inc. | Pharma & chemicals | 54.2 | — | 1.5× | -39.2% | −2.3σ |
| 89 | QTTB | Q32 Bio Inc. Common Stock | Pharma & chemicals | 54.1 | 6.5× | 4.0×FY | -12.6% | +1.2σ |
| 90 | ALKS | Alkermes Inc. plc | Pharma & chemicals | 54.1 | 51.2× | 5.0× | 2.8% | −0.4σ |
| 91 | CC | The Chemours Company | Pharma & chemicals | 54.1 | — | 0.4× | 6.6% | +0.5σ |
| 92 | TROX | TRONOX LIMITED CL A ORDINARY SHARES | Pharma & chemicals | 53.8 | — | 0.3× | -32.5% | −2.5σ |
| 93 | FTK | Flotek Industries, Inc. | Pharma & chemicals | 53.8 | 28.8× | 3.4× | -0.0% | +0.8σ |
| 94 | ABEO | Abeona Therapeutics Inc. Common Stock | Pharma & chemicals | 53.5 | 5.0× | 57.2×FY* | -25.6% | +0.5σ |
| 95 | FF | Future Fuel Corporation | Pharma & chemicals | 52.9 | — | 2.1× | -26.8% | −2.7σ |
| 96 | DNA | Ginkgo Bioworks Holdings, Inc. | Pharma & chemicals | 52.8 | — | 2.8× | -40.1% | −0.3σ |
| 97 | ELF | e.l.f. Beauty, Inc. | Pharma & chemicals | 52.7 | 245×FY | 3.9×FY | 2.9%FY | +1.3σ |
| 98 | SEPN | Septerna, Inc. Common Stock | Pharma & chemicals | 52.6 | — | 23.7× | 6.2% | — |
| 99 | LIN | Linde plc Ordinary Share | Pharma & chemicals | 52.3 | 32.5× | 6.6× | 2.2% | −0.8σ |
| 100 | CSW | CSW Industrials, Inc. | Pharma & chemicals | 52.2 | 45.9×FY | 4.8×FY | 2.6%FY | −1.1σ |
"Cheap composite" is a 0–100 position among valid sector peers — the mean of the component metrics' sector percentiles. "—" means the scan published no figure, deliberately. "n/a — masked" means the metric is misleading in that name's sector (a REIT's GAAP P/E, a bank's FCF yield) — hover for the reason, which comes from the same sector-validity rules the composite itself respects. An FY tag marks a trailing-year figure built from an annual filing; hover for what that means.